Bibliography
- Amato I. Pulling Genes' Strings. C&EN 2006;84(29):13-8
- Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52
- Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606
- Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001;10:693-8
- Butler LM, Agus DB, Scher HI, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
- FDA approval and New Drug Application (NDA) documents for ZolinzaTM (SAHA, vorinostat) Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_ZolinzaTOC.cfm
- De Ruijter AJ, Van Gennip AH, Caron HN, Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49
- Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13
- Gantt SL, Gattis SG, Fierke CA. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 2006;45:6170-8
- Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-20
- Curtin M, Glaser K. Histone deacetylase inhibitors: the abbott experience. Curr Med Chem 2003;10:2373-92
- Glaser KB, Li J, Staver MJ, Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36
- Balasubramanian S, Ramos J, Luo W, A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34
- Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31
- Haggarty SJ, Koeller KM, Wong JC, Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389-94
- Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21
- Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50
- Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51
- Wilson KJ, Witter DJ, Grimm JB, Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorg Med Chem Lett 2008;18:1859-63
- Heidebrecht RW Jr, Chenard M, Close J, Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2009;19:2053-8
- Witter DJ, Harrington P, Wilson KJ, Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18:726-31
- Andrews DM, Stokes ES, Carr GR, Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:2580-4
- Hamblett CL, Methot JL, Mampreian DM, The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2007;17:5300-9.
- Methot JL, Hamblett CL, Mampreian DM, SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18:6104-9
- The Ohio State Research Foundation. WO2007040522; 2007
- Gloucester Pharmaceuticals, Inc. WO2007061939; 2007
- Price S, Dyke HJ. Histone deacetylase inhibitors: an analysis of recent patenting activity. Expert Opin Ther Patents 2007;17:745-65
- Weinmann E, Ottow E. Histone deacetylase inhibitors: a survey of recent patents. Expert Opin Ther Patents 2005;15:1677-90
- Khan N, Jeffers M, Kumar S, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9
- Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem 2008;51:1505-29 and additions and corrections. J Med Chem 2008;51:3330
- Wang H, Yu N, Chen D, Discovery of SB939, an HDAC inhibitor with a superior preclinical profile (Abstract No. 136). 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, Oct 21-24, 2008. (poster). Available from: http://www.sbio.com/main/posters/2008/SBIO_EORTC_Oct08_Discovery%20of%20SB939.pdf
- Altana Pharma A-G. WO27039404; 2007 and WO2007039403; 2007
- Chroma Therapeutics Ltd. WO2008040934; 2008
- Buggy JJ, Cao ZA, Bass KE, CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006;5:1309-17
- Janssen Pharmaceutica NV. WO2008031817A2; 2008
- Kulp SK, Chen CS, Wang DS, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006;12:5199-206
- Fournel M, Bonfils C, Hou Y, MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:759-68
- Shenzhen Chipscreen Biosciences Ltd. US07244751B2; 2007
- CUDC-101 presentation Available from: http://www.curis.com/AACR2008CUDC101liver.pdf
- Curis, Inc. US7547781; 2009 and US2008/013950A1; 2008
- Korea Research Institute of Chemical Technology and Crystal Genomics, Inc. WO2008054154 (2008)
- Methylgene, Inc. WO2009055917; 2009
- China Pharmaceutical University. CN101230049A; 2008
- Orchid Research Laboratories Limited. WO2007017728; 2007
- Methylgene, Inc. WO2007022638; 2007
- Methylgene, Inc. and en vivo Pharmaceuticals. WO2008055068; 2008
- Merck & Co., Inc. WO2009045385; 2009
- Janssen Pharmaceutica NV. WO2007082880; 2007
- Janssen Pharmaceutica NV. WO2007082882; 2007
- Janssen Pharmaceutica NV. 2007082873; 2007
- Janssen Pharmaceutica NV. WO2008138918; 2008
- Janssen Pharmaceutica NV. WO2007082874; 2007
- Janssen Pharmaceutica NV. WO2007048767; 2007
- The J. David Gladstone Institutes and Ithaca college. WO2008101186; 2008
- Krennhrubec K, Marshall BL, Hedglin M, Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17:2874-8
- Zhejiang Hisun Pharmaceutical Co., Ltd. and Central South University of China. WO2009067856; 2009
- Shandong University. CN101255124A; 2008
- Orchid Research Laboratories Limited. WO2009053808; 2009
- Orchid Research Laboratories Limited. WO2008087514; 2008
- DAC SRL. WO29027395; 2009
- DAC SRL. WO2007113249; 2007
- Available from: http://www.genextra.it/docs/DAC0060_press_release_08_10_28.pdf
- Astellas Pharma Inc. WO2007091703; 2007
- Astellas Pharma Inc. WO2008075757; 2008
- China Pharmaceutical University. CN101148442A; 2008.
- Su H, Nebbioso A, Carafa V, Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. Bioorg Med Chem 2008;16:7992-8002
- Tokyo University and the Institute of Physical & Chemical Research (RIKEN). JP2007077085A; 2007
- Lee S, Shinji C, Ogura K, Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007;17:4895-900
- S*BIO Pte Ltd: WO2007030080; 2007 and US20090048300; 2009
- S*BIO Pte Ltd. WO2008036046; 2007
- S*BIO Pte Ltd. US2008085896; 2008
- The President and Fellows of Harvard College. WO2007130429; 2007
- Universidad De Granada. WO2008003800; 2008
- Universidad De Granada. WO2008003801; 2008
- Sigma-Tau Industrie Farmaceutiche Riunite SPA. WO2008110583; 2008
- Orchid Research Laboratories Limited. WO2007113644; 2007
- Georgetown University. WO2008019025A2; 2008
- Arqule, Inc. WO2009026446; 2009
- UPV-EHU and CNIO. WO2007074176; 2007
- Orchid Research Laboratories Limited. WO2007054776; 2007
- Korea Research Institute of Chemical Technology and Crystal Genomics, Inc. WO2007052938; 2007
- Methylgene Inc. WO2008074132A1; 2008
- Methylgene Inc. WO2008122115A1; 2008
- Methylgene Inc. US2009023798A1; 2009
- University College London and Barts and the London NHS Trust. WO2008047138; 2008
- Jackson, William Paul. WO2008068170; 2008
- The President and Fellows of Harvard College and Dana-Farber Cancer Institute. WO2008091349; 2008.
- The President and Fellows of Harvard College and Dana-Farber Cancer Institute, Inc. WO2007095584; 2007
- Chroma Therapeutics Ltd. WO2008053131; 2008
- Merck & Co., Inc. US2009156825A1; 2009
- Georgetown University. WO2009079375A1; 2009
- Merck & Co., Inc. WO2007127137; 2007
- Merck & Co., Inc. WO2007100657; 2007
- Merck & Co., Inc. WO2007002248; 2007
- Merck & Co., Inc. WO2007055941; 2007
- Merck & Co., Inc. WO2008010985; 2008
- Merck & Co., Inc. WO2009020589; 2009
- Merck & Co., Inc. WO2009002495; 2009
- Merck & Co., Inc. WO2009005638; 2009
- Gilead Colorado, Inc. WO2009079391; 2009
- Takeda San Diego, Inc. WO2007011626; 2009
- Takeda San Diego, Inc. WO2007084390; 2007
- Takeda San Diego, Inc. WO2008089436; 2008
- Astrazeneca AB and Astrazeneca UK Ltd. WO2007045844; 2007
- Methylgene Inc. WO2007118137; 2007
- Methylgene Inc. WO2008109994; 2008
- Syndax Pharmaceuticals. WO2009015237; 2009
- Astrazeneca AB and Astrazeneca UK Ltd. WO2007071956; 2007
- Astrazeneca AB and Astrazeneca UK Ltd. WO2007071961; 2007.
- Merck & Co., Inc. WO2007087129; 2007
- Merck & Co., Inc.: WO2007087130; 2007.
- SC AG. WO2009037001; 2009
- Merck & Co., Inc. WO2007055942; 2007
- Merck & Co., Inc. US2007117824; 2007
- Merck & Co., Inc. WO2007136605; 2007
- Janssen Pharmaceutica NV. WO2007082876; 2007
- Janssen Pharmaceutica NV. WO2007082878; 2007
- Santen Pharmaceutical Co., Ltd. WO2008117862; 2008
- The Scripps Research Institute. WO2007058927; 2007
- Karus Therapeutics Limited. WO2008062201; 2008
- University of Southampton. WO28062232; 2008
- Karus Therapeutics Limited. WO2009022182; 2009
- The Board of Regents, the University of Texas System. WO29002941; 2009
- FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma. Available from: http://www.gloucesterpharma.com/press/releases/pr090209.html
- Kyushu Institute of Technology, Japan; Riken Corp. WO2008029565; 2008
- Georgia Tech Research Corporation. WO2009006403; 2009.
- Oyelere AK, Chen PC, Guerrant W, Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem 2009;52:456-68
- Istituto Di Ricerche Di Biologia Molecolare P. AngelettI SPA. WO2007029036; 2007
- Istituto Di RicerChe Di Biologia Molecolare P. Angeletti SPA. WO2007072080; 2007
- Pescatore G, Kinzel O, Attenni B, Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:5528-32
- Jones P, Altamura S, De Francesco R, A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem 2008;51:2350-3
- Kinzel O, Llauger-Bufi L, Pescatore G, Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J Med Chem 2009;52:3453-6
- Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA. WO2007029035; 2007
- Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA. WO2007093827; 2007
- Muraglia E, Altamura S, Branca D, 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:6083-7
- Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA. WO2007107594; 2007
- Orchid Research Laboratories Limited. WO2007045962; 2007
- Kalypsys, Inc. WO2007016354; 2007
- Kalypsys, Inc. WO2007067994; 2007
- Kalypsys, Inc. WO2008073733; 2008
- Payne Je, Bonnefous C, Hassig CA, Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg Med Chem Lett 2008;18:6093-6
- Wash PL, Hoffman TZ, Wiley BM, alpha-Mercaptoketone based histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:6482-5
- Syndax Pharmaceuticals, Inc. WO29015203; 2009
- Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA. WO2007052073; 2008
- Lixte Biotechnology Holdings, Inc. WO2009045440; 2009
- Methylgene Inc. WO2007143822; 2007
- Wahhab A, Smil D, Ajamian A, Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett 2009;19:336-40
- Manku S, Allan M, Nguyen N, Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. Bioorg Med Chem Lett 2009;19:1866-70
- Nudelman A, Rephaeli A. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J Med Chem 2000;43:2962-6
- Curis, Inc. WO2008033747; 2008
- SC AG. WO2009063054; 2009
- Curis, Inc. WO2009035718; 2009
- Curis, Inc. WO2008033748; 2008
- Curis, Inc. WO2008033749; 2008
- Curis, Inc. WO2009036055; 2009
- Curis, Inc. WO2009036057; 2009
- Curis, Inc. WO2009036066; 2009
- Curis, Inc.: WO28033743; 2008
- Shenzhen Chipscreen Biosciences, Ltd. US2009182029; 2009
- Shenzhen Chipscreen Biosciences, Ltd. WO2009014941; 2009
- Curis, Inc. WO2008033745; 2008
- Curis, Inc. WO2009036016; 2009
- Gilead Colorado, Inc. WO2009002534; 20081231
- Curis, Inc. WO2009036020; 2009
- Curis, Inc. WO2008033746; 2008
- Curis, Inc. WO2008115263; 2008
- Curis, Inc. WO2008115262; 2008
- Curis, Inc. WO2009036012; 2009
- Curis, Inc. WO2008033744; 2008
- Centre National De La Recherche Scientifique, FR. WO2008125988; 2008
- Mcgill University (CAN). WO2007131364; 2007
- Curis, Inc. WO2009036051; 2009
- Regents of the University of Minnesota. WO2009018344; 2009
- Imperial Innovations Ltd. WO2008050125; 2008
- Arts J, Angibaud P, Mariën A, R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 2007;97:1344-53
- Zain JM, Foss F, Kelly WK, Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol 2009;27(15S):, abstract 8580
- Kummar S, Gutierrez M, Gardner ER, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13:5411-7
- Gore L, Rothenberg ML, O'bryant CL, A phase i and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14:4517-25
- Siu LL, Pili R, Duran I, Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7
- Dong M, Ning Z, Newman MJ, Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol 2009;27(15S):, abstract 3529
- Yong W, Goh B, Toh H, Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies. J Clin Oncol 2009;27(15S):, abstract 2560
- Brunetto AT, Ang JE, Lal R, A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009;27(15S):, abstract 3530
- SC-201 and Sorafenib in Advanced Hepatocellular Carcinoma (Shelter) Available from: http://clinicaltrials.gov/ct2/show/NCT00943449?term=HDAC&rank=59
- Hassig CA, Symons KT, Guo X, KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:1054-65
- Feng R, Ma H, Hassig CA, KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 2008;7:1494-505
- Vannini A, Volpari C, Filocamo G, Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;19:15064-9
- Somoza JR, Skene RJ, Katz BA, Structural snapshots of human HDAC8 provide insights into the class i histone deacetylases. Structure 2004;12:1325-34
- Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class i histone deacetylases. J Med Chem 2005;48:6936-47
- Ficner R. Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem 2009;9:235-40
- Wiech NL, Fisher JF, Helquist P, Wiest O. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem 2009;9:257-71
- Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009;9(3):309-19
- Leoni F, Fossati G, Lewis EC, The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15
- Leoni F, Zaliani A, Bertolini G, The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002;99:2995-3000
- Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA). Available from: http://clinicaltrials.gov/ct2/show/NCT00570661?term=ITF2357&rank=2